Compass Therapeutics, Inc. (CMPX)

Market Cap	726.57M
Revenue (ttm)	n/a
Net Income (ttm)	-65.81M
Shares Out	177.86M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,076,051
Open	4.000
Previous Close	4.000
Day's Range	3.805 - 4.125
52-Week Range	1.270 - 4.860
Beta	1.30
Analysts	Strong Buy
Price Target	14.43 (+253.24%)
Earnings Date	Nov 5, 2025

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPX
• Website: https://www.compasstherapeutics.com

Analyst Summary

According to 7 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $14.43, which is an increase of 253.24% from the latest price.

Price Target

$14.43

(253.24% upside)

Analyst Consensus: Strong Buy